Human methylome studies SRP405928 Track Settings
 
Optimized bisulfite sequencing reveals the lack of 5-methylcytosine in mammalian mitochondrial DNA [WGBS] [Brain, Breast Cancer Cell, Embryonic Kidney Cell, Embryonic Stem Cell, Hepatocarcinoma Cell, Lung Adenocarcinoma Cell, Melanoma Cell, Neuroblastoma Cell, Platelet]

Track collection: Human methylome studies

+  All tracks in this collection (426)

Maximum display mode:       Reset to defaults   
Select views (Help):
PMD       CpG methylation ▾       CpG reads ▾       AMR      
Select subtracks by views and experiment:
 All views PMD  CpG methylation  CpG reads  AMR 
experiment
SRX18122821 
SRX18122822 
SRX18122823 
SRX18122824 
SRX20687273 
SRX20687274 
List subtracks: only selected/visible    all    ()
  experiment↓1 views↓2   Track Name↓3  
hide
 SRX18122821  AMR  Embryonic Kidney Cell / SRX18122821 (AMR)   Data format 
hide
 SRX18122821  PMD  Embryonic Kidney Cell / SRX18122821 (PMD)   Data format 
hide
 Configure
 SRX18122821  CpG methylation  Embryonic Kidney Cell / SRX18122821 (CpG methylation)   Data format 
hide
 Configure
 SRX18122821  CpG reads  Embryonic Kidney Cell / SRX18122821 (CpG reads)   Data format 
hide
 SRX18122822  AMR  Breast Cancer Cell / SRX18122822 (AMR)   Data format 
hide
 SRX18122822  PMD  Breast Cancer Cell / SRX18122822 (PMD)   Data format 
hide
 Configure
 SRX18122822  CpG methylation  Breast Cancer Cell / SRX18122822 (CpG methylation)   Data format 
hide
 Configure
 SRX18122822  CpG reads  Breast Cancer Cell / SRX18122822 (CpG reads)   Data format 
hide
 SRX18122823  AMR  Hepatocarcinoma Cell / SRX18122823 (AMR)   Data format 
hide
 SRX18122823  PMD  Hepatocarcinoma Cell / SRX18122823 (PMD)   Data format 
hide
 Configure
 SRX18122823  CpG methylation  Hepatocarcinoma Cell / SRX18122823 (CpG methylation)   Data format 
hide
 Configure
 SRX18122823  CpG reads  Hepatocarcinoma Cell / SRX18122823 (CpG reads)   Data format 
hide
 SRX18122824  AMR  Hepatocarcinoma Cell / SRX18122824 (AMR)   Data format 
hide
 SRX18122824  PMD  Hepatocarcinoma Cell / SRX18122824 (PMD)   Data format 
hide
 Configure
 SRX18122824  CpG methylation  Hepatocarcinoma Cell / SRX18122824 (CpG methylation)   Data format 
hide
 Configure
 SRX18122824  CpG reads  Hepatocarcinoma Cell / SRX18122824 (CpG reads)   Data format 
hide
 SRX20687273  AMR  Platelet / SRX20687273 (AMR)   Data format 
hide
 SRX20687273  PMD  Platelet / SRX20687273 (PMD)   Data format 
hide
 Configure
 SRX20687273  CpG methylation  Platelet / SRX20687273 (CpG methylation)   Data format 
hide
 Configure
 SRX20687273  CpG reads  Platelet / SRX20687273 (CpG reads)   Data format 
hide
 SRX20687274  AMR  Platelet / SRX20687274 (AMR)   Data format 
hide
 SRX20687274  PMD  Platelet / SRX20687274 (PMD)   Data format 
hide
 Configure
 SRX20687274  CpG methylation  Platelet / SRX20687274 (CpG methylation)   Data format 
hide
 Configure
 SRX20687274  CpG reads  Platelet / SRX20687274 (CpG reads)   Data format 
    
Assembly: Human Dec. 2013 (GRCh38/hg38)

Study title: Optimized bisulfite sequencing reveals the lack of 5-methylcytosine in mammalian mitochondrial DNA [WGBS]
SRA: SRP405928
GEO: not found
Pubmed: not found

Experiment Label Methylation Coverage HMRs HMR size AMRs AMR size PMDs PMD size Conversion Title
SRX18122821 Embryonic Kidney Cell 0.405 3.2 7141 13115.2 1553 12864.4 772 955570.4 0.995 GSM6705308: HEK293T; Homo sapiens; Bisulfite-Seq
SRX18122822 Breast Cancer Cell 0.409 3.2 8545 5081.5 3073 8357.0 670 1087289.0 0.995 GSM6705309: MCF7; Homo sapiens; Bisulfite-Seq
SRX18122823 Hepatocarcinoma Cell 0.390 3.9 885 35847.9 429 65301.7 1400 1140040.6 0.993 GSM6705310: HepG2; Homo sapiens; Bisulfite-Seq
SRX18122824 Hepatocarcinoma Cell 0.229 4.6 4678 4307.8 191 101904.4 615 2056427.6 0.995 GSM6705311: HepG2, mtDNA enriched; Homo sapiens; Bisulfite-Seq
SRX20687273 Platelet 0.706 4.0 20973 1432.2 303 88505.1 356 54301.7 0.992 GSM7493481: Platelet1; Homo sapiens; Bisulfite-Seq
SRX20687274 Platelet 0.739 4.1 23632 1406.4 274 98231.4 355 54888.8 0.992 GSM7493482: Platelet2; Homo sapiens; Bisulfite-Seq

Methods

All analysis was done using a bisulfite sequnecing data analysis pipeline DNMTools developed in the Smith lab at USC.

Mapping reads from bisulfite sequencing: Bisulfite treated reads are mapped to the genomes with the abismal program. Input reads are filtered by their quality, and adapter sequences in the 3' end of reads are trimmed. This is done with cutadapt. Uniquely mapped reads with mismatches/indels below given threshold are retained. For pair-end reads, if the two mates overlap, the overlapping part of the mate with lower quality is discarded. After mapping, we use the format command in dnmtools to merge mates for paired-end reads. We use the dnmtools uniq command to randomly select one from multiple reads mapped exactly to the same location. Without random oligos as UMIs, this is our best indication of PCR duplicates.

Estimating methylation levels: After reads are mapped and filtered, the dnmtools counts command is used to obtain read coverage and estimate methylation levels at individual cytosine sites. We count the number of methylated reads (those containing a C) and the number of unmethylated reads (those containing a T) at each nucleotide in a mapped read that corresponds to a cytosine in the reference genome. The methylation level of that cytosine is estimated as the ratio of methylated to total reads covering that cytosine. For cytosines in the symmetric CpG sequence context, reads from the both strands are collapsed to give a single estimate. Very rarely do the levels differ between strands (typically only if there has been a substitution, as in a somatic mutation), and this approach gives a better estimate.

Bisulfite conversion rate: The bisulfite conversion rate for an experiment is estimated with the dnmtools bsrate command, which computes the fraction of successfully converted nucleotides in reads (those read out as Ts) among all nucleotides in the reads mapped that map over cytosines in the reference genome. This is done either using a spike-in (e.g., lambda), the mitochondrial DNA, or the nuclear genome. In the latter case, only non-CpG sites are used. While this latter approach can be impacted by non-CpG cytosine methylation, in practice it never amounts to much.

Identifying hypomethylated regions (HMRs): In most mammalian cells, the majority of the genome has high methylation, and regions of low methylation are typically the interesting features. (This seems to be true for essentially all healthy differentiated cell types, but not cells of very early embryogenesis, various germ cells and precursors, and placental lineage cells.) These are valleys of low methylation are called hypomethylated regions (HMR) for historical reasons. To identify the HMRs, we use the dnmtools hmr command, which uses a statistical model that accounts for both the methylation level fluctations and the varying amounts of data available at each CpG site.

Partially methylated domains: Partially methylated domains are large genomic regions showing partial methylation observed in immortalized cell lines and cancerous cells. The pmd program is used to identify PMDs.

Allele-specific methylation: Allele-Specific methylated regions refers to regions where the parental allele is differentially methylated compared to the maternal allele. The program allelic is used to compute allele-specific methylation score can be computed for each CpG site by testing the linkage between methylation status of adjacent reads, and the program amrfinder is used to identify regions with allele-specific methylation.

For more detailed description of the methods of each step, please refer to the DNMTools documentation.